SOUTH SAN FRANCISCO, Calif., Aug. 31, 2016 -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will present at two upcoming investor conferences:
- 2016 Wells Fargo Healthcare Conference
Wednesday, September 7th at 2:20 PM Eastern Time
The Westin Boston Waterfront, Boston - Rodman & Renshaw 18th Annual Global Investment Conference
Tuesday, September 13th at 2:10 PM Eastern Time
Lotte New York Palace Hotel, New York
Live webcasts of the presentations will be available on the Sunesis website at http://ir.sunesis.com. Replays of the webcasts will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to improving the lives of people with cancer. Currently, the company is focused on pursuing regulatory approval in Europe for its lead product candidate, vosaroxin, for the treatment of relapsed or refractory acute myeloid leukemia in patients aged 60 and older, as well as advancing its novel kinase-inhibitor pipeline, which includes its proprietary non-covalent BTK-inhibitor, SNS-062.
For additional information on Sunesis, please visit http://www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717


Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 



